CN111346121B - 牛膝活性提取物的新用途 - Google Patents
牛膝活性提取物的新用途 Download PDFInfo
- Publication number
- CN111346121B CN111346121B CN202010300995.9A CN202010300995A CN111346121B CN 111346121 B CN111346121 B CN 111346121B CN 202010300995 A CN202010300995 A CN 202010300995A CN 111346121 B CN111346121 B CN 111346121B
- Authority
- CN
- China
- Prior art keywords
- achyranthes bidentata
- active
- extract
- virus
- active extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 240000000031 Achyranthes bidentata Species 0.000 claims abstract description 41
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 244000052769 pathogen Species 0.000 claims abstract description 8
- 230000001154 acute effect Effects 0.000 claims abstract description 6
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims abstract description 6
- 238000002386 leaching Methods 0.000 claims abstract description 6
- 230000002458 infectious effect Effects 0.000 claims abstract description 5
- 244000045947 parasite Species 0.000 claims abstract description 5
- 241000233866 Fungi Species 0.000 claims abstract description 4
- 239000000287 crude extract Substances 0.000 claims abstract description 4
- 208000030090 Acute Disease Diseases 0.000 claims abstract description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims abstract description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims abstract description 3
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 3
- 238000011033 desalting Methods 0.000 claims abstract description 3
- 238000010828 elution Methods 0.000 claims abstract description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 3
- 230000009545 invasion Effects 0.000 claims abstract description 3
- 238000001556 precipitation Methods 0.000 claims abstract description 3
- 238000000926 separation method Methods 0.000 claims abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 2
- 230000002314 neuroinflammatory effect Effects 0.000 claims abstract 2
- 210000000274 microglia Anatomy 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 8
- 241000427159 Achyranthes Species 0.000 claims description 7
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000003959 neuroinflammation Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 241000193468 Clostridium perfringens Species 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000305071 Enterobacterales Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 2
- 241000710886 West Nile virus Species 0.000 claims description 2
- 229940065181 bacillus anthracis Drugs 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 7
- 230000010287 polarization Effects 0.000 abstract description 6
- 238000009835 boiling Methods 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 description 26
- 229920006008 lipopolysaccharide Polymers 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 10
- 230000004900 autophagic degradation Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 230000002025 microglial effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 102100020814 Sequestosome-1 Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108090000426 Caspase-1 Proteins 0.000 description 3
- 102100035904 Caspase-1 Human genes 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 210000001642 activated microglia Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 description 2
- 108010034143 Inflammasomes Proteins 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 102100024177 Microtubule-associated proteins 1A/1B light chain 3B Human genes 0.000 description 2
- 101710171597 Microtubule-associated proteins 1A/1B light chain 3B Proteins 0.000 description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000011475 meningoencephalitis Diseases 0.000 description 2
- 230000006724 microglial activation Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical class C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- -1 sterone Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了牛膝活性提取物在制备治疗中枢神经系统感染性炎症性疾病药物中的新用途,所述牛膝活性提取物的制备步骤包括:(1)牛膝活性粗提物的制备将单味药材怀牛膝饮片粉碎,水煮浸提,将浸提液用硫酸铵分级沉淀,将沉淀透析除盐得到牛膝活性肽粗提物;(2)牛膝活性提取物的HPLC分离:使用C18制备柱进行梯度洗脱。本发明牛膝活性提取物能够调节中枢神经系统先天免疫细胞极化表型,减轻神经炎性损伤的药理作用显著,可用于研发治疗中枢神经系统生物性病原体(包括细菌、病毒、真菌、寄生虫等)侵犯中枢神经系统实质、被膜及血管等引起的急性或慢性炎症性疾病的药物和保健品。
Description
技术领域
本发明属于天然药物领域,具体涉及一种牛膝活性提取物的新用途。
背景技术
中枢神经系统感染性疾病,指各种生物性病原体(包括细菌、病毒、立克次体、螺旋体、寄生虫、真菌、寄生虫等)侵犯中枢神经系统实质、被膜及血管等所引起的急性或慢性炎症性(或非炎症性)疾病。根据受累部位可分为三类:主要侵犯脑和脊髓实质的脑(脊髓)炎、主要侵犯脑(脊髓)膜的脑(脊)膜炎、脑实质与脑膜合并受累的脑膜脑炎。根据病原体可分为:细菌性、病毒性、真菌性、寄生虫性等。根据发病情况和病程可分为:急性、亚急性、慢性。根据病例特点可分为:包涵体性、出血性、坏死性、脱髓鞘性等。其中细菌引起的脑膜炎是最常见的中枢神经系统感染,与细菌三种成分有关:细菌包膜、细菌的细胞壁、脂多糖物质。革兰氏阳性菌的细胞壁含有大量的多糖肽和壁酸,革兰氏阴性菌的细胞壁含有脂多糖分子,这些物质都引起强烈的脑膜炎性反应。而病毒性脑炎,如单纯疱疹脑炎的脑组织中可见血管周围大量小胶质细胞活化、巨噬细胞、淋巴细胞等炎性细胞浸润,神经元死亡。中枢神经系统感染性疾病的治疗原则,包括给予抗菌或抗病毒或免疫抑制治疗以控制病情、控制早期并发症、预防迟发性并发症。具体地,主要是采用抗生素或清除病灶等手段消灭或抑制病原体,调节机体的体液及细胞免疫机制以增强防御及修复能力。校正或调节病理生理机制以减轻炎性反应对靶器官的损害,保护脑功能,注意水电解质的平衡等亦是冶疗中极为重要的辅助手段。
小胶质细胞是中枢神经系统内固有的免疫效应细胞,正常脑组织中,小胶质细胞呈高度分枝状,以大约每小时一次的频率与神经元突触发生直接接触,为大脑提供一个高度动态和高效的监测系统。在大脑发育的早期阶段,小胶质细胞参与对中枢神经系统内神经元数量的调控。当脑内发生炎症、感染、创伤或其他神经系统疾病时,小胶质细胞迅速被激活,介导中枢神经系统损伤和疾病的内源性免疫反应,发挥神经保护或神经毒性作用。激活的小胶质细胞胞体增大、突起变短、细胞形态呈阿米巴样,其活化状态与脑内受损部位的严重程度密切相关,并且呈现不同的功能表型,包括经典激活型(M1型)和替代激活型(M2型),M1型小胶质细胞具有促炎作用,可释放炎症因子,破坏血脑屏障、抑制神经再生,M2型小胶质细胞具有抗炎作用,可释放保护性的营养因子,营养神经、促进神经修复、促进血管再生。随着对小胶质细胞激活表型的认识越来越深入,干预神经炎症的策略已从完全抑制小胶质细胞活化转为调节其激活表型,在正确的时间提高适当的功能表型,进而减轻炎性损伤、促进神经修复的作用。寻找能调节小胶质细胞极化表型使其向有利于神经损伤修复方向发展的有效药物,是当今医药研究中引人关注的课题。
天然药物应用历史悠久、多靶点作用、疗效良好、毒副作用小,具有从中开发新型药物的潜在价值。近年来越来越多具有神经保护作用的天然药物活性成分也相继被分离出来,但尚未有植物活性肽成分调节小胶质细胞极化表型进而防治神经系统感染性炎症的报道。
牛膝(Achyranthes bidentata Bl.)为苋科牛膝属植物,常用其根入药,味苦、甘、酸,性平,归肝、肾经,能活血通经、补肝肾、强筋骨、利水通淋、引火下行,可用于腰膝酸痛、筋骨无力、肝阳眩晕等证。牛膝含多糖、皂苷、甾酮、甾醇、香豆素和生物碱等成分,另外还含有少量挥发油、无机盐和氨基酸(多肽或蛋白质)。
专利号201310108655.6公开了一种可用于促进神经生长,防治神经损伤以及防止神经退行性变的牛膝活性提取物及其制备方法与用途,研究表明该多肽活性提取物能够促进小鼠背根神经节神经元突起生长,增加神经元突起延长和分支,促进小鼠神经再生和功能恢复。牛膝活性提取物能减轻施万细胞氧化损伤,增强抗氧化酶活性,抑制PI3K/Akt和ERK1/2信号通路调控的细胞凋亡,从而促进周围神经再生。
发明内容
本发明的目的在于在现有技术的基础上,进一步提供牛膝活性提取物的新用途。
本发明所述的牛膝活性提取物采用专利201310108655.6公开的技术方案获得。
本发明具体技术方案如下:
牛膝活性提取物在制备治疗中枢神经系统感染性病理性神经炎症及其相关疾病的药物中的应用,所述牛膝活性提取物采用专利201310108655.6公开的技术方案获得,具体步骤包括:
(1)牛膝活性粗提物的制备:将单味药材怀牛膝饮片粉碎,水煮浸提,将浸提液使用饱和度为50%和80%的硫酸铵盐溶液进行分级沉淀,将沉淀透析除盐得到牛膝活性肽粗提物;
(2)牛膝活性提取物的HPLC分离:使用C18制备柱,流动相A为含有0.1%TFA的H2O,流动相B为含有0.1%TFA的CH3CN,梯度洗脱条件为:0min:80%流动相A,20%流动相B;30min:47%流动相A,53%流动相B;31min:100%流动B,收集保留时间23.352min的组分。
本发明所述中枢神经系统感染性炎症为生物性病原体侵犯中枢神经系统实质、被膜或血管引起的急性或慢性炎症性疾病。
进一步的,所述生物性病原体选自细菌、病毒、真菌、寄生虫中的一种或几种。
所述细菌选自脑膜炎双球菌、肺炎球菌、嗜血流感杆菌、大肠杆菌、金黄色葡萄球菌、绿脓杆菌、各种肠道杆菌、链球菌、炭疽杆菌、产气荚膜杆菌等中的一种或几种。
所述病毒包括单纯疱疹病毒、水痘带状疱疹病毒、EV病毒、巨细胞病毒、腺病毒、流行性感冒病毒、轮状病毒、麻疹病毒、狂犬病毒、西尼罗河病毒、蜱传脑炎病毒等中的一种或几种。
本发明以脂多糖(LPS)刺激的BV2小胶质细胞作为细胞模型,研究了本发明所述牛膝活性提取物对小胶质细胞自噬功能、极化表型、炎性小体产生、吞噬功能以及炎症因子释放的影响。LPS是细菌内毒素,用来模拟革兰氏阴性菌感染。结果表明,本发明所述牛膝活性提取物能够激活LPS刺激下小胶质细胞的自噬功能,抑制M1型小胶质细胞的激活,促进并维持M2型小胶质细胞激活,抑制炎性小体的产生,促进小胶质细胞吞噬功能,抑制炎症因子的释放,其安全性高,药理作用显著,可用于研发治疗中枢神经系统感染性疾病的药物和保健品。
附图说明
图1为牛膝活性提取物对小胶质细胞自噬功能的调节(A.泛素结合蛋白SQSTM1和自噬相关蛋白LC3B的Western blot印迹图,B.SQSTM1蛋白印迹灰度分析图,C.LC3BII与LC3BI蛋白印迹灰度比值分析图,D.LC3B的免疫荧光细胞化学染色图)。
图2为牛膝活性提取物对小胶质细胞极化的调节(A.免疫荧光化学染色显示M1型小胶质细胞标志蛋白CD16+32与小胶质细胞标志蛋白Iba-1随着时间变化在BV2细胞中的共定位及荧光强度的变化,B.免疫荧光化学染色显示M2型小胶质细胞标志蛋白CD206与小胶质细胞标志蛋白Iba-1随着时间变化在BV2细胞中的共定位及荧光强度的变化)。
图3为牛膝活性提取物对小胶质细胞炎性小体产生的影响。
图4为牛膝活性提取物对小胶质细胞吞噬功能的影响。
图5为牛膝活性提取物对小胶质细胞炎症因子释放的影响(A.牛膝活性提取物对LPS刺激BV2小胶质细胞后产生TNF-α水平的影响,B.牛膝活性提取物对LPS刺激BV2小胶质细胞后产生IL-6水平的影响)。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不是用于限制本发明的应用范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明做各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
采用专利201310108655.6公开的技术方案制备得到牛膝活性提取物。
实施例1牛膝活性提取物对小胶质细胞自噬功能的调节
体外采用6孔培养板培养BV2小胶质细胞,接种密度为2×105细胞/ml,24h后加入5μg/ml牛膝活性提取物处理30min,再加入1μg/ml脂多糖(LPS)处理细胞24h,弃去培养液,用PBS漂洗一遍,加入150μl/孔含1%蛋白酶抑制剂的细胞裂解液,冰上裂解30min,用蛋白刮子收集裂解产物,涡旋3min后4℃、15000rpm离心30min,收集上清。采用BCA蛋白定量法定量后进行Western blot分析。向蛋白样品中加入SDS-PAGE蛋白上样缓冲液(5×)稀释至1×,涡旋振荡,煮沸10min,取蛋白样品10μg进行10%SDS-PAGE,电泳电压150V,1h;采用湿转法于冰水浴中转至PVDF膜,恒流300mA,2h;转膜结束后,将膜置于含5%脱脂奶粉的TBS-T中,室温于摇床上包被1h,加一抗:用5%脱脂奶粉稀释一抗SQSTM 1(1:1000)、LC3B(1:1000),4℃摇床过夜,TBS-T洗三次,每次10min,加二抗:用TBS-T稀释二抗IRDye 800goat-anti-mouse或goat-anti-rabbit IgG(1:5000),室温下避光孵育2h。TBS-T洗5遍,每遍5min,显色后用全自动化学发光/荧光图像分析系统,加Beyo ECL Star于膜上进行灰度扫描,采用Image J软件分析结果。以β-actin作内参,实验重复3次。体外采用24孔培养板培养BV2小胶质细胞,接种密度为2×105细胞/ml,24h后加入5μg/ml牛膝活性提取物处理30min,再加入1μg/ml脂多糖处理细胞24h后,采用自噬标志蛋白LC3B免疫细胞化学染色,荧光显微镜下观察、拍照,采用图像分析系统分析荧光强度。结果如图1所示(A.泛素结合蛋白SQSTM1和自噬相关蛋白LC3B的Western blot印迹图,B.SQSTM1蛋白印迹灰度分析图,C.LC3BII与LC3BI蛋白印迹灰度比值分析图,D.LC3B的免疫荧光细胞化学染色图),结果显示,培养不同时间后,牛膝活性提取物能显著促进背根神经节突起的生长。LPS刺激导致BV2细胞泛素结合蛋白SQSTM 1表达上调,自噬流(LC3BII/LC3BI比值)下降,提示LPS抑制了小胶质细胞自噬功能,而牛膝活性提取物组SQSTM 1表达下调,自噬流增高。与Western blot分析结果一致,细胞免疫荧光化学染色图也显示,牛膝活性提取物组LC3B蛋白从胞膜上的I型向胞浆中的II型转化增多,表明牛膝活性提取物激活了小胶质细胞的自噬功能。
实施例2牛膝活性提取物对小胶质细胞极化表型的调节
体外采用24孔培养板培养BV2小胶质细胞,接种密度为2×105细胞/ml,24h后加入5μg/ml牛膝活性提取物处理30min,再加入1μg/ml脂多糖处理细胞2h,6h及24h后,分别采用M1型和M2型小胶质细胞的标志蛋白CD16+32和CD206免疫细胞化学染色,荧光显微镜下观察、拍照,采用图像分析系统分析荧光强度,结果如图2所示(A.免疫荧光化学染色显示M1型小胶质细胞标志蛋白CD16+32与小胶质细胞标志蛋白Iba-1随着时间变化在BV2细胞中的共定位及荧光强度的变化,B.免疫荧光化学染色显示M2型小胶质细胞标志蛋白CD206与小胶质细胞标志蛋白Iba-1随着时间变化在BV2细胞中的共定位及荧光强度的变化),LPS刺激2h,LPS组与牛膝活性提取物组的M1型(CD16+32+)小胶质细胞均不明显,而与LPS组相比,牛膝活性提取物组M2型(CD206+)小胶质细胞明显增多,且一直维持至24h;LPS刺激6h,LPS组M1型小胶质细胞增多,而牛膝活性提取物组M1型小胶质细胞显著减少,且一直维持至24h。表明牛膝活性提取物能够促进并维持M2型小胶质细胞的表达,抑制M1型小胶质细胞的表达。
实施例3牛膝活性提取物对小胶质细胞炎性小体产生的影响
体外采用6孔培养板培养BV2小胶质细胞,接种密度为2×105细胞/ml,24h后加入5μg/ml牛膝活性提取物处理30min,再加入1μg/ml脂多糖处理细胞24h,弃去培养液,用PBS漂洗一遍,加入150μl/孔含1%蛋白酶抑制剂的细胞裂解液,冰上裂解30min,用蛋白刮子收集裂解产物,涡旋3min后4℃、15000rpm离心30min,收集上清。采用BCA蛋白定量法定量后进行Western blot分析。向蛋白样品中加入SDS-PAGE蛋白上样缓冲液(5×)稀释至1×,涡旋振荡,煮沸10min,取蛋白样品10μg进行10%SDS-PAGE,电泳电压150V,1h;采用湿转法于冰水浴中转至PVDF膜,恒流300mA,2h;转膜结束后,将膜置于含5%脱脂奶粉的TBS-T中,室温于摇床上包被1h,加一抗:用5%脱脂奶粉稀释一抗NLRP3(1:1000)、caspase 1(1:1000)和IL-1β(1:1000),4℃摇床过夜,TBS-T洗三次,每次10min,加二抗:用TBS-T稀释二抗IRDye800goat-anti-mouse或goat-anti-rabbit IgG(1:5000),室温下避光孵育2h。TBS-T洗5遍,每遍5min,显色后用全自动化学发光/荧光图像分析系统,加Beyo ECL Star于膜上进行灰度扫描,采用Image J软件分析结果。以β-actin作内参,实验重复3次。结果如图3所示,LPS组NLRP3、caspase 1(p10)和IL-1β表达均升高,而牛膝活性提取物组NLRP3、caspase 1(p10)和IL-1β表达均显著下降。
实施例4牛膝活性提取物对小胶质细胞吞噬功能的影响
体外采用24孔培养板培养BV2小胶质细胞,接种密度为2×105细胞/ml,24h后加入5μg/ml牛膝活性提取物处理30min,再加入10μg/mlβ-淀粉酶(Aβ)处理细胞24h后,分别采用小胶质细胞标志物Iba-1和外源性Aβ免疫细胞化学染色,荧光显微镜下观察、拍照,结果如图4所示,牛膝活性提取物预处理的BV2细胞对Aβ的吞噬明显增多。
实施例5牛膝活性提取物对小胶质细胞炎症因子释放的影响
体外采用6孔培养板培养BV2小胶质细胞,接种密度为2×105细胞/ml,24h后加入5μg/ml牛膝活性提取物处理30min,再加入1μg/ml LPS处理细胞24h后,收集上清,分别采用TNF-α和IL-6ELISA试剂盒检测TNF-α和IL-6的释放量,结果如图5所示(A.牛膝活性提取物对LPS刺激BV2小胶质细胞后产生TNF-α水平的影响,B.牛膝活性提取物对LPS刺激BV2小胶质细胞后产生IL-6水平的影响),LPS刺激24h会导致BV2小胶质细胞TNF-α和IL-6产生增多,而牛膝活性提取物可显著抑制TNF-α和IL-6的释放。
Claims (4)
1.牛膝活性提取物在制备治疗中枢神经系统感染性炎症性疾病的药物中的应用,所述牛膝活性提取物采用如下方法制备得到,步骤包括 :
(1)牛膝活性粗提物的制备:将单味药材怀牛膝饮片粉碎,水煮浸提,将浸提液使用饱和度为50%和80%的硫酸铵盐溶液进行分级沉淀,将沉淀透析除盐得到牛膝活性粗提物;
(2)牛膝活性提取物的 HPLC 分离:使用 C18 制备柱,流动相 A 为含有 0.1%TFA 的H2O,流动相 B 为含有 0.1%TFA 的 CH3CN,梯度洗脱条件为:0 min:80%流动相 A,20% 流动相 B;30min:47%流动相 A,53%流动相 B;31min:100%流动 B,收集保留时间 23.352 min的组分,
所述神经炎症为生物性病原体侵犯中枢神经系统实质、被膜或血管引起的急性或慢性炎症性疾病,所述生物性病原体选自细菌、病毒、真菌、寄生虫中的一种或几种。
2.根据权利要求 1所述的应用,其特征在于所述细菌选自脑膜炎双球菌、肺炎球菌、嗜血流感杆菌、大肠杆菌、金黄色葡萄球菌、绿脓杆菌、各种肠道杆菌、链球菌、炭疽杆菌、产气荚膜杆菌的一种或几种。
3.根据权利要求1所述的应用,其特征在于所述病毒选自单纯疱疹病毒、水痘带状疱疹病 毒、EV 病毒、巨细胞病毒、腺病毒、流行性感冒病毒、轮状病毒、麻疹病毒、狂犬病毒、西尼罗河病毒、蜱传脑炎病毒中的一种或几种。
4.根据权利要求1所述的应用,其特征在于所述牛膝活性提取物通过激活小胶质细胞,产生 M2 型小胶质细胞减轻急慢性神经炎症反应。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010300995.9A CN111346121B (zh) | 2020-04-16 | 2020-04-16 | 牛膝活性提取物的新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010300995.9A CN111346121B (zh) | 2020-04-16 | 2020-04-16 | 牛膝活性提取物的新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111346121A CN111346121A (zh) | 2020-06-30 |
CN111346121B true CN111346121B (zh) | 2021-12-10 |
Family
ID=71189609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010300995.9A Active CN111346121B (zh) | 2020-04-16 | 2020-04-16 | 牛膝活性提取物的新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111346121B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101270147A (zh) * | 2008-04-18 | 2008-09-24 | 南通大学 | 牛膝多肽及生产方法和用途 |
CN104083420A (zh) * | 2013-04-01 | 2014-10-08 | 南通大学 | 牛膝活性提取物及其制备方法与用途 |
-
2020
- 2020-04-16 CN CN202010300995.9A patent/CN111346121B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101270147A (zh) * | 2008-04-18 | 2008-09-24 | 南通大学 | 牛膝多肽及生产方法和用途 |
CN104083420A (zh) * | 2013-04-01 | 2014-10-08 | 南通大学 | 牛膝活性提取物及其制备方法与用途 |
Non-Patent Citations (1)
Title |
---|
牛膝多肽对多巴胺能神经元的保护作用研究;彭苏;《医药卫生科技辑》;20181030;第36页第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN111346121A (zh) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wong et al. | Neuroregenerative potential of lion's mane mushroom, Hericium erinaceus (Bull.: Fr.) Pers.(higher Basidiomycetes), in the treatment of peripheral nerve injury | |
Wong et al. | Activity of aqueous extracts of lion's mane mushroom Hericium erinaceus (Bull.: Fr.) Pers.(Aphyllophoromycetideae) on the neural cell line NG108-15 | |
Yang et al. | Buyang huanwu decoction combined with BMSCs transplantation promotes recovery after spinal cord injury by rescuing axotomized red nucleus neurons | |
KR102341932B1 (ko) | 장미 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 항염, 상처 치료 또는 상처 치료 촉진용 조성물 | |
Ma et al. | Chemical characterization of polysaccharides isolated from scrophularia ningpoensis and its protective effect on the cerebral ischemia/reperfusin injury in rat model | |
Maslova et al. | Astrocytes and their phenomenal possibilities in the treatment of various neurodegenerative disorders: An overview | |
DE68909100T2 (de) | Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon. | |
Zhang et al. | Update on new trend and progress of the mechanism of polysaccharides in the intervention of Alzheimer's disease, based on the new understanding of relevant theories: a review | |
WO2015190872A1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 | |
CN118178591A (zh) | 一种防治膝骨关节炎的中药组合物及其应用 | |
CN111346121B (zh) | 牛膝活性提取物的新用途 | |
KR101734093B1 (ko) | 알러지 유발 물질을 저감시킨 정제 봉독을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물 | |
Chen et al. | Transplantation of bone marrow mesenchymal stem cells alleviates spinal cord injury via inhibiting Notch signaling. | |
KR101771788B1 (ko) | 신경 질환의 예방 및 개선용 발효황금 천마복합액의 제조방법 | |
CN113925871A (zh) | 大蓟苷在制备神经炎症抑制剂中的用途 | |
IL194346A (en) | Tripeptide having a stimulating effect on the regeneration of neurons and pharmaceutical composiions comprising it | |
Han et al. | Preventive effect of small molecular fraction of Irpex lacteus (Agaricomycetes) fruiting body against chronic nephritis in mice and identification of active compounds | |
CN110882286A (zh) | 去壁灵芝孢子粉的用途 | |
WO2002017931A1 (fr) | Utilisation d'un ou de plusieurs extraits de tripterygium wilfordii hook.f pour la preparation de medicaments destines a prevenir et a traiter des troubles du systeme nerveux | |
TWI586367B (zh) | 磷酸甘油酯激酶增加神經突生長及/或治療神經性疾病的用途 | |
CN110577942A (zh) | 一种用于提高视网膜色素上皮细胞吞噬功能的活性肽及其应用 | |
TWI813993B (zh) | 一種靈芝液態發酵液用於製備預防、改善或治療阿茲海默症或阿茲海默症引起的相關病症的組合物之用途 | |
CN114949013B (zh) | 黄水枝醇提物在制备治疗或保护、调节阿尔兹海默症疾病药物中的应用 | |
KR102514847B1 (ko) | 병풀, 벌사상자 및 영하구기자 추출물을 포함하는 인지 기능 장애 또는 신경염증의 예방 또는 치료용 조성물 | |
WO2002006341A1 (en) | A trophic factor capable of producing a neurosalutary effect in a subject |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |